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AbstrAct
The specific and rapid detection of Enterobacteriaceae, the most frequent cause 
of gram-negative bacterial infections in humans, remains a major challenge. We 
developed a non-invasive method to rapidly detect systemic Yersinia enterocolitica 
infections using immunoPET (antibody-targeted positron emission tomography) 
with [64Cu]NODAGA-labeled Yersinia-specific polyclonal antibodies targeting the 
outer membrane protein YadA. In contrast to the tracer [18F]FDG, [64Cu]NODAGA-
YadA uptake co-localized in a dose dependent manner with bacterial lesions of 
Yersinia-infected mice, as detected by magnetic resonance (MR) imaging. This 
was accompanied by elevated uptake of [64Cu]NODAGA-YadA in infected tissues, 
in ex vivo biodistribution studies, whereas reduced uptake was observed following 
blocking with unlabeled anti-YadA antibody. We show, for the first time, a bacteria-
specific, antibody-based, in vivo imaging method for the diagnosis of a Gram-negative 
enterobacterial infection as a proof of concept, which may provide new insights into 
pathogen-host interactions.
INtrODUctION
Nuclear medicine enables the early and accurate 
detection of inflammation and infection, with the potential 
for clinically diagnosing infectious diseases. Molecular 
imaging using positron emission tomography (PET) 
allows the metabolic and functional activities of living 
cells to be determined, and when combined with pathogen-
specific tracers, permits the distinction between normal 
and pathological tissues [1]. A limitation of PET is the 
availability of pathogen-specific tracers that allow for the 
discrimination between different infectious etiologies and 
between sites of sterile inflammation [2-3]. Furthermore, 
most of the radiopharmaceuticals used are not pathogen-
specific and accumulate at the sites of inflammation [4] 
thereby restricting the diagnostic capabilities of the 
technology. 
Fluorine-18 fluorodeoxyglucose ([18F]FDG), 
the major clinical PET tracer used for the detection of 
malignancies, has been used for imaging of infectious 
diseases [5]. However, as a general indicator of metabolic 
activity of cells, it does not allow for the specific 
identification of pathogens at sites of inflammation 
[6]. An increasing number of innovative PET 
radiopharmaceuticals employing monoclonal antibodies or 
their fragments, peptides, and small molecules have been 
developed and evaluated for infectious disease imaging, 
mainly in preclinical settings [7], but compared to tracer 
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development in cancer research, its use for the specific 
detection of pathogens is in its infancy.
The Gram-negative bacterium Yersinia enterocolitica 
(Ye) belongs to the family Enterobacteriaceae and is an 
important cause of gastrointestinal infections. Infections 
are caused by ingestion of contaminated food or drinking 
water and can cause severe diarrhea, enterocolitis, and 
mesenteric lymphadenitis [8]. In immunocompromised 
patients, systemic infection can lead to focal abscesses in 
the spleen and liver [9]. Similar clinical manifestations 
have been found in a murine model of systemic Yersinia 
infection, with Ye also being detectable in the lymph 
nodes, bone marrow and lungs at one day post-infection 
[10-11]. The virulence of Ye is associated with Yersinia 
adhesin A (YadA), a trimeric autotransporter that mediates 
cell adhesion. Its presence on the cell surface makes it 
an ideal biomarker candidate for the specific imaging of 
yersiniosis [12].
The aim of this study was to evaluate the diagnostic 
potential of a newly developed 64Cu-labeled polyclonal 
antibody targeting YadA for used as a PET tracer and to 
compare its accuracy to that of [18F]FDG for the detection 
of Ye infections in a well-established mouse model of 
yersiniosis that closely resembles the course of infection in 
humans [13]. In the study presented here, we demonstrate 
a dramatically improved sensitivity and specificity of the 
antibody-based tracer in detecting Ye infection compared 
to the use of [18F]FDG. The experimental Ye infection 
used here mimics yersiniosis in humans [13] and thus 
offers excellent opportunities for basic in vivo research on 
newly developed immunoPET tracers for the diagnosis of 
pathogen-induced inflammation.
rEsULts
Infection of mice with Ye impairs their 
physiological condition
To evaluate conventional PET tracers for their use 
in the detection of systemic Ye infection, we first assessed 
the physiological conditions of the mice after intravenous 
(i.v.) injections of two different doses of Ye, a sub-lethal 
dose (1x103 Ye, indicated as the low dose) and a lethal 
dose (5x104 Ye, indicated as the high dose), or an injection 
with PBS as the control (Figure 1A). No significant 
differences in the body weights of the different animal 
groups were observed throughout the infection period 
(Figure 1B), although marginal weight loss was observed 
in mice due to the infection and/or anesthesia. Throughout 
the infection period, the blood glucose levels and the water 
and food intake levels of the high-dose-infected animals 
were significantly lower than those of the PBS-treated and 
low-dose-infected mice (Figure 1C). 
The spleen size of the animals was assessed in vivo 
via volumetric measurements using MRI and was found 
to be correlated with the severity of infection (Figure 1D). 
Consistent with this, the bacterial load was significantly 
higher in the spleens of the high-dose- than it was in the 
low-dose-infected mice (Figure 1E). Bacteria were also 
detected in the liver and bone marrow of the high-dose- 
but not of the low-dose-infected mice (Figure 1F and 1G). 
Thus, the spleen is the major focus of Ye replication, and 
moderate infection leads to the eradication of the bacteria 
and the subsequent recovery of the mice, while severe 
infection results in an overwhelming infection and death.
PEt-Mr imaging of Ye with [18F]FDG
The clinical PET tracer [18F]FDG, commonly 
employed for oncological purposes, was used to image 
systemic Ye infection in mice. For in vivo evaluation of 
the tracer, Ye-infected and PBS-treated mice were i.v. 
injected with 12-14 MBq of [18F]FDG on days 1, 2 and 
3 post-infection (p.i.), and PET and MRI scanning data 
were acquired after an uptake time of 60 min (Figure 2A). 
A high uptake of [18F]FDG in the spleen of high-dose-
infected mice was observed throughout the infection. A 
slight increase in tracer uptake upon high-dose infection 
was also observed in the spine, liver and brain (Figure 
2, Figure S2, Table S1). Upon infection with a low dose 
of Ye, marginal [18F]FDG uptake was observed in the 
spleen but not in other organs, and there was no difference 
relative to the PBS-treated mice (Figure S2 and Table 
S1). The PET imaging data were confirmed by an ex vivo 
biodistribution analysis after the last PET/MRI scan on 
day 3 p.i. (Table S2).
PEt-Mr imaging with the Ye-specific tracer 
[64cu]NODAGA-YadA
To specifically detect Ye infection using PET 
imaging, we developed a Ye-specific tracer based on 
a 64Cu-labeled polyclonal antibody targeting the outer 
membrane protein YadA. The radiochemical purities of 
NODAGA-YadA and the Aspergillus-specific control 
antibody NODAGA-JF5 were 85-95 % and 65 %, 
respectively, after labeling with 64Cu. The remaining 64Cu 
was bound to unconjugated NODAGA, and the fraction 
of uncomplexed 64Cu2+ was below 5 % in both cases. The 
specific activity in two independent labeling procedures 
was 650-730 MBq/mg for NODAGA-YadA and 500 
MBq/mg for NODAGA-JF5. For the assessment of the 
serum stability, one volume of [64Cu]NODAGA-YadA in 
its final formulation was incubated with three volumes of 
C57BL/6 serum at 37 °C for various lengths of time and 
immediately analyzed via radio-HPSEC (Figure S4A) and 
autoradiography (Figure S4B). The radiochemical purity 
for up to 48 h remained above 90 %, and the analysis 
showed no signs of proteolytic degradation, protein 
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Figure 1: Physiological changes upon Yersinia infection. A. Schematic showing the experimental procedure (scheme adapted from 
[46]). Mice were infected with low-dose (1x103 CFU; n = 7) or high-dose (5x104 CFU; n = 7) Ye or treated with PBS and were analyzed one 
to three days p.i. for b. body weight, c. blood glucose level, and D. spleen volume via MRI and for bacterial load (CFU) in the E. spleen, F. 
liver, and G. bone marrow. Data are shown as the means ± SD from one out of two or more independent experiments. See also, Figure S1.
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aggregation or copper transchelation to serum proteins 
over the 48 h period under these conditions (Figure S4C). 
The immunoreactivity of the YadA antibody following 
labeling with the chelator NODAGA was investigated via 
immunofluorescence using YadA-expressing (positive) 
and non-YadA-expressing (negative) Ye or E. coli 
bacteria. The labeling of the antibody with the chelator 
did not alter the specific binding of the antibody to its 
target YadA antigen (Figure S5). Intense fluorescence 
of the YadA-positive Ye or E. coli and a lack of staining 
of the non-YadA-expressing bacteria were observed in 
each case. PET imaging showed a high uptake of the 
radiolabeled [64Cu]NODAGA-YadA polyclonal antibody 
in the spleens of low-dose- and high-dose-infected mice 
throughout the infection period in a dose-dependent 
manner. A significantly lower uptake was observed in the 
spleens of PBS-treated control mice (Figure 3, Figure S3). 
Blocking experiments were performed by injecting 500 
µg of non-radiolabeled anti-YadA antibody 3 h prior to the 
injection of radiolabeled [64Cu]NODAGA-YadA into high-
dose-infected mice to determine the in vivo specificity of 
the newly developed PET tracer. Blocking was already 
evident 24 h after the injection, with significantly lower 
uptake of the radiolabeled tracer observed in the spleens 
Figure 2: Quantification of PET images with the [18F]FDG tracer in Ye-infected mice. A. Schematic showing the experimental 
procedure (scheme adapted from [46]). The mice were divided into three groups: group 1, control (not infected); group 2, low dose-
infected; group 3, high dose-infected. Mice were infected with 5 x 104 (high dose) or 1 x 103 (low dose) CFU of Y. enterocolitica i.v. at day 
1. The imaging protocol included sequential PET/MR imaging of uninfected control and Ye-infected mice on 3 consecutive days. Coronal 
[18F]FDG PET and fused PET and MR images from PBS-treated and low- and high-dose-infected mice 3 days p.i. b.. Arrows indicate the 
positions of the spleen. Fiducial markers used for co-registration of the PET and MR images are marked with an x. c. Quantitative analysis 
of the [18F]FDG uptake in the spleen is shown (black bars, PBS treated controls (n = 3); blue bars, low-dose-infected mice n = 7); red bars, 
high-dose-infected mice (n = 7-8). Data are shown as the means ± SD (%ID/cc). See also, Figure S2 and Tables S1, S2 and S3.
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Figure 3: Quantification of PET images with the [64cu]NODAGA-YadA tracer in Ye-infected mice. A. Schematic showing 
the experimental procedure (scheme adapted from [46]). The mice were divided into three groups: group 1, control (not infected); group 2, 
low-dose-infected; group 3, high-dose-infected. Mice were infected with 5 x 104 (high dose) or 1 x 103 (low dose) CFU of Y. enterocolitica 
i.v. at day -1. All groups received a single i.v. injection with the respective [64Cu]NODAGA-labeled antibody and were sequentially imaged 
via PET/MR on 3 consecutive days. Coronal [64Cu]NODAGA-YadA PET and fused PET and MR images from PBS-treated and low- and 
high-dose-infected mice 3 days p.i. b.. Administration of polyclonal non-radiolabeled YadA antibody 3 h prior to the injection of [64Cu]
NODAGA-YadA (to block YadA) or the administration of the Aspergillus-specific tracer [64Cu]NODAGA-JF5 (control mAb) into high-
dose-infected mice served as the control treatments. Arrows indicate the positions of the spleens in the mice. c. Quantification of the PET 
images as measured in b. the quantitative analysis of [64Cu]NODAGA-YadA or [64Cu]NODAGA-JF5 uptake in the spleen is shown. D. Ex 
vivo biodistribution of the tracer [64Cu]NODAGA-YadA in the depicted organs. (black bars, PBS (n = 5); blue bars, low-dose Ye (n = 5); 
red bars, high-dose Ye (n = 5); red dashed bars, high-dose Ye blocked with 500 µg non-labeled YadA antibody (n = 5); green bars, high-dose 
Ye imaged with the Aspergillus-specific tracer [64Cu]NODAGA-JF5 (n = 4). Data are shown as the means ± SD. See also, Figure S3 and 
Tables S5 and S6.
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of mice treated with the blocking antibody than were 
observed in the spleens of the non-blocked high-dose-
infected mice (Figure 3B, Figure S3; Table S3). The tracer 
[64Cu]NODAGA-JF5, which included the Aspergillus-
specific monoclonal antibody JF5 [14], was used as an 
additional control and showed significantly lower uptake 
than was observed in the other treatment groups (Figure 
3). The quantified results for the tested organs are shown 
in Supplement Table S3 and were confirmed by the ex vivo 
biodistribution data (Figure 3C and Table S4).
Immunohistochemistry and antibody-based 
analysis
To confirm the PET results, sections of the 
spleens from all groups of mice were analyzed via 
immunohistochemistry. Macroscopically, the PBS-treated 
and low-dose Ye-infected mice had normal sized spleens, 
whereas the spleens of the high-dose-infected animals 
were enlarged. Additionally, the spleens of the high-dose-
infected mice showed signs of lymphoid hyperplasia, with 
germinal centers and multiple abscesses detected by H&E 
staining (Figure 4). 
Figure 4: Immunohistochemistry supports the data from PEt imaging. Immunohistochemical staining of spleen tissue sections 
from PBS-treated, low-dose- and high-dose-infected mice 3 days p.i. Administration of the polyclonal non-radiolabeled antibody YadA 3 
h prior to injection of the [64Cu]NODAGA-YadA (to block YadA) into high-dose-infected mice served as control treatment. Sections were 
stained for H&E, Glut-1, and the goat anti-rabbit secondary antibody to detect the in vivo administered YadA (blocking) antibody. All the 
magnifications are indicated. Inserts show Glut-1 (630x) and the anti-YadA Ab (400x). Data are representative of 12 analyzed mice.
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Spleens were further analyzed for Glut-1 expression, 
an indicator of the degree of glucose metabolism. Slight 
Glut-1 staining was observed in the periphery of the 
splenic white pulp of the PBS-treated and low-dose-
infected animals, with no difference detectable between 
these groups. In contrast, Glut-1 expression was elevated, 
especially in the necrotic areas of abscesses, in the spleens 
of high-dose-infected animals (Figure 4). These data 
support the results obtained from the [18F]FDG imaging 
that showed increased FDG uptake in the spleens of 
high-dose-infected mice but not in those from low-dose-
infected mice.
To confirm the blocking experiment with the YadA 
antibody applied prior to the Ye-specific tracer, splenic 
sections were stained with a secondary antibody that 
detects the blocking antibody. Positive staining for this 
antibody was only observed in the abscesses caused 
by Ye in the sections of spleens from mice treated with 
the blocking antibody YadA ([500 µg/mouse]). The 
concentration of the Ye tracer [64Cu]NODAGA-YadA was 
too low ([20 µg/mouse]) to be detected in the spleens 
of the low-dose and high-dose infected animals via 
immunohistochemistry.
DIscUssION
Infectious pathogens are a serious health issue, 
and their accurate detection remains a major challenge 
in medicine. Effective treatment relies on pathogen 
identification at an early stage of the infection, and 
yet, many infections remain undiagnosed prior to their 
systemic manifestation [7]. Nuclear imaging has emerged 
as a rapid, non-invasive and highly sensitive approach to 
disease diagnosis, which can identify sites of infection 
and inflammation more rapidly than conventional 
laboratory-based diagnostic techniques [15]. These 
traditional diagnostic modalities often result in long turn-
around times, making it more difficult when dealing with 
contaminants, thereby, compelling clinicians to treat 
patients empirically with broad-spectrum antibiotics until 
diagnostic results are available [16-17].
Existing tracers for PET imaging are not able to 
distinguish between malignancies and sterile or pathogen-
induced inflammations [18-19]. Furthermore, at the late 
stages of an infection, it is even more challenging to 
correctly diagnose the cause of the illness because the 
disease can manifest non-pathogen-induced symptoms 
similar to those observed in malignancies [20]. Here, we 
present a novel pathogen-specific imaging tracer for use in 
the non-invasive dose-dependent detection and diagnosis 
of a bacterial infection of humans. Enterobacteriaceae 
are the most common cause of Gram-negative bacterial 
infections. To investigate the specificity of our tracer, we 
used a well-established [21] Enterobacteriaceae-sepsis 
mouse model, with the intravenous administration of Ye. 
Consistent with previous studies, the pathogen was mainly 
found within the spleen, liver and, to a lesser extent, 
bone marrow [10]. The radiolabeled anti-YadA antibody, 
which binds to the outer membrane protein Ye adhesin A 
(YadA), was able to specifically detect the pathogen in 
vivo. Notably, the anti-YadA antibody used in this study 
targets a pathogenic factor essential for in vivo virulence, 
highlighting the specificity of the newly developed PET 
tracer. [64Cu]NODAGA-YadA uptake occurred in an 
infection dose-dependent manner, demonstrating the 
sensitivity of the new tracer and its ability to discriminate 
lethal and sub-lethal infections. Furthermore, a constantly 
elevated uptake of the [64Cu]NODAGA-YadA tracer was 
observed over time in low-dose- and high-dose-infected 
animals, independent of their bacterial burden. In contrast, 
elevated uptake of the standard PET tracer [18F]FDG was 
only observed in the spleen of high-dose Ye-infected 
mice, which was accompanied by a slight increase in 
[18F]FDG uptake by the spine, liver and brain. However, 
blood glucose levels were elevated in both low- and high-
dose-infected animals. These results indicate that while 
the tracer [18F]FDG is able to detect severe inflammation 
in high-dose-infected mice, glucose metabolism during 
sub-lethal infections appears to not be increased as 
shown by consistently unaltered tracer uptake. This may 
be explained by the induction of inflammation and the 
increased [18F]FDG uptake caused by activated immune 
cells at the infection site [6, 22] rather than by the bacteria 
themselves, as there was no correlation with the bacterial 
loads. The comparable 18[F]FDG uptake in the spleen 
of low-dose-infected and uninfected mice is probably 
due to the physiological uptake pattern of [18F]FDG in 
this organ resulting in a ‘false negative’ detection of the 
tracer in low-dose-infected mice. This is in agreement 
with the findings of other groups that have shown that 
[18F]FDG is nonspecific in PET oncological applications 
[23-24]. Furthermore, [18F]FDG is unable to detect early 
stage bacterial infections and, in some instances, shows 
increased signal intensities after effective antibiotic 
treatments [25]. Nevertheless, it is currently the principal 
tracer used for the imaging of infectious diseases in 
humans [20, 26].
The application of whole-body immunoPET 
imaging to the field of infectious diseases is in its 
infancy [27]. It has been most recently used to detect 
SIV (simian immunodeficiency virus) infections in 
macaques [28]. For bacterial infections, several PET 
tracers using antibiotics, peptides, antibodies and 
radiolabeled white blood cells have been developed and 
tested in preclinical studies, but so far, they have had a 
limited clinical impact [18, 29]. More recently, sugar 
transporters for sorbitol and maltose or an alternative 
sugar transporter, the bacterial universal phosphate 
transporter (UHPT), have been investigated as targets for 
bacteria-specific imaging using 2-[18F]fluorodeoxysorbitol 
([18F]FDS) [17], 6-[18F]fluoromaltose (MH18F) [29], 
and an analogue of glucose, [18F]FDG-6-P [30]. Using 
Oncotarget8www.impactjournals.com/oncotarget
these tracers, it is possible to distinguish between 
Gram-negative (e.g., Enterobacteriaceae) and Gram-
positive (e.g., Staphylococcus aureus) bacteria. [18F]FDS 
has recently been shown to be highly sensitive in the 
detection of E. coli, with a detection limit of 6.2 ± 0.2 log
10
 
CFU [17]. In contrast, [64Cu]NODAGA-YadA allowed 
the detection of as few as 3.5 ± 0.4 log
10
 CFU Ye in the 
spleen, demonstrating the high sensitivity of our tracer. 
Recently, an Aspergillus-specific monoclonal antibody has 
been used to enable the use of immunoPET/MR imaging 
for the diagnosis of invasive pulmonary aspergillosis 
(IPA). The PET tracer [64Cu]DOTA-JF5 was able to 
distinguished IPA from bacterial lung infections and, in 
contrast to [18F]FDG-PET, was able to discriminate IPA 
from a general increase in metabolic activity associated 
with lung inflammation. This work demonstrates the 
applicability of molecular imaging for antibody-guided 
detection and its potential for aiding clinical diagnoses 
and the management of infectious diseases [31]. The 
highly Aspergillus-specific NODAGA-labeled monoclonal 
antibody JF5 was used in this study as a Ye nonspecific 
control antibody. In general, intact antibodies are highly 
specific molecules and constitute, along with other 
molecules, the first-line of defense against pathogens. The 
bivalent binding properties of antibodies provide a high 
affinity and avidity for their specific antigens. Antibodies 
for immunoPET, labeled directly or via chelators, possess 
great potential for disease-specific imaging and are already 
used in clinics for immunoPET imaging, mainly for cancer 
diagnostics [32-34]. The ideal imaging agents should be 
characterized by an intrinsic serum stability, good target 
uptake and persistence, non-immunogenicity, and optimal 
clearance from the circulation to obtain the highest signal 
differences [33, 35]. Native antibodies (150 kDa) are 
known to have a long serum half-life, possibly causing 
inadvertent irradiation and toxicity to healthy tissue when 
radiolabeled and used as immunoPET tracers [36]. One 
approach to overcome these drawbacks is to reduce the 
size of the antibodies. Using genetic engineering, defined 
antibody fragments can be constructed and produced [34, 
37]. The reduced size of mAb fragments leads to a much 
faster serum clearance, which results in higher target-to-
reference-tissue ratios at earlier time points compared to 
results obtained from the use of parental antibodies. The 
disadvantages of radiolabeled antibody fragments are their 
accumulation in the kidneys, which can possibly cause 
high radiation doses [38-39] similar to standard small 
molecule tracers used in clinics, and their varying degree 
of specificity for the detection of infections. An advantage 
of the long in vivo serum half-life of full length antibodies 
is that, when used as immunoPET tracers, they allow 
for the repeated imaging of patients following a single 
injection of the radiolabeled tracer, thereby, enabling the 
monitoring of disease progression, pathogen dissemination 
and responses to treatment.
A limitation of the present study was that a clear 
identification of the pathogen in the liver tissue was not 
possible due to the nonspecific uptake of the radiolabeled 
antibody and the free-copper accumulation, which 
resulted in a high PET signal. The nonspecific uptake of 
radiolabeled antibodies in the liver is a common finding 
[40-42]. Thus, in this organ, nonspecific uptake cannot be 
distinguished from specific [64Cu]NODAGA-YadA uptake 
by Ye.
Our work is, to the best of our knowledge, the 
first example of immunoPET imaging for the rapid, 
sensitive and specific detection of infection by a human 
enteropathogenic bacterium. Thus, we show a proof of 
concept for the use of [64Cu]NODAGA-labeled pathogen-
specific antibodies as candidates for use as imaging probes 
in preclinical testing. We propose that our approach using 
[64Cu]NODAGA-anti-YadA could be adapted to detect 
other bacterial pathogens via immunoPET. Future efforts 
should also focus on class-specific antibodies for the 
detection and differentiation of pathogenic bacteria.
MAtErIALs AND MEtHODs
Mice, infection and bacterial load
All animal procedures were carried out according to 
protocols approved by the Regierungspräsidium Tübingen 
(IZ1/10). Female C57BL/6JOlaHsd mice were infected 
with 5 x 104 (high dose) or 1 x 103 (low dose) CFU of 
Ye WA-314 (serotype 0:8) via injection into the tail vein. 
Mice were sacrificed 1, 2 or 3 days p.i. and the organs 
were weighed. Some portions were frozen for histology 
and other portions were homogenized to determine the 
bacterial load, which was obtained after plating serial 
dilutions of the cell suspensions on Müller-Hinton agar 
plates. For PET/MR imaging, a separate group of mice 
was used and analyzed on 3 consecutive days.
PEt tracer production
Fluorine-18 was produced as [18F]fluoride in a 
PETtrace cyclotron using the 18O(p, n)18F nuclear reaction, 
and [18F]FDG was synthesized as described elsewhere 
[43]. To generate the Ye-specific PET tracer, whole serum 
from rabbits that had been immunized with purified 
YadA protein [44] was used for the purification of the 
IgG fraction. NODAGA NHS Ester (Chematech, Dijon, 
France) was  conjugated with the antibody in Chelex 100 
(Sigma-Aldrich)  treated phosphate-buffered saline at a 
molar ratio of 55:1  for 18 h. Excess chelator was removed 
using seven  sequential ultrafiltration steps with PBS. 
For radiolabeling, copper-64 was produced as described 
previously [45] and  incubated with the NODAGA-
conjugated antibody for 1 h at 42 °C.
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serum stability of the chelator-conjugated YadA 
antibody
For serum stability tests, one volume of [64Cu]
NODAGA-YadA (after clean-up with a Bio-Spin 6 
column) was incubated with three volumes of C57BL/6 
serum at 37 °C. Samples were removed after 0 h, 1 h, 3 
h, 24 h and 48 h and immediately analyzed using radio-
HPSEC. Retention times for void volume, reference IgG 
and internal volume were 3.34 min, 5.67 min and 8.82 
min, respectively. In addition, samples were run on iTLC-
SG paper with 0.1 M sodium citrate (pH 5) and analyzed 
via autoradiography.
PEt/Mr imaging and ex vivo biodistribution
The imaging protocol included sequential PET/MR 
imaging of uninfected control and Ye-infected mice on 
three consecutive days. The animals were treated/infected 
as described above and scanned on days 1, 2 and 3 p.i. 
Mice were imaged using a small-animal PET scanner 
(Inveon, Siemens Preclinical Solutions, Knoxville, TN, 
USA), which yielded a spatial resolution of approximately 
1.3 mm in the reconstructed images. All of the animals 
were briefly anaesthetized with 1.5 % isoflurane mixed 
with 100 % oxygen at a flow rate of 0.8 L/min and injected 
i.v. with 12-14 MBq of [18F]FDG via a lateral tail vein. For 
[18F]FDG imaging, mice were kept under anesthesia with 
1.5 % isoflurane mixed with 100 % oxygen at a flow rate 
of 0.8 L/min in a 37 °C heated anesthesia chamber for 60 
min. For immunoPET imaging, mice were injected with 
20 µg of either the [64Cu]NODAGA-labeled anti-YadA 
antibody or the [64Cu]NODAGA-labeled Aspergillus-
specific JF5 control mAb, which corresponded to 12-
14 MBq. For the blocking studies, 500 µg of the non-
radiolabeled YadA antibody was injected 3 h prior to the 
injection of the tracer. Ten-minute static PET scans were 
acquired after the uptake time of the F-18 labeled tracer 
(Figure 2A) and 3, 24 and 48 h after the injection of the 
[64Cu]NODAGA-labeled tracers (Figure 3A). During 
the PET and magnetic resonance (MR) imaging, the 
animals were anesthetized with 1.5 % isoflurane mixed 
with 100 % oxygen. PET data were acquired in list-mode, 
histogrammed in one 10-min time frame and reconstructed 
using an iterative ordered subset expectation maximization 
(OSEM) algorithm. No attenuation corrections were 
applied. MR imaging was performed on a 7 T small 
animal MR tomography system (Clinscan, Bruker 
Biospin MRI, Ettlingen, Germany) to obtain anatomical 
information. A T2-weighted 3D-space sequence (TE / TR 
202 / 2500 ms, image matrix of 137 x 320, slice thickness 
0.27 mm) was used for whole-body imaging. PET images 
were normalized to each other and subsequently fused 
to their respective MR images and analyzed using the 
Inveon Research Workplace software (Siemens Preclinical 
Solutions). Regions of interest (ROIs) were drawn 
around the respective tissues based on the anatomical 
information from the MR images. Volumetric data from 
the spleens were assessed based on the PET/MR data 
using these ROIs. Absolute quantification of the PET data 
are expressed as a percentage of the injected dose (%ID/
cc). Blood was collected via a retrobulbar puncture from 
the anesthetized mice prior to tracer administration, and 
glucose was immediately measured in a HemoCue glucose 
system (HemoCue GmbH, Grossostheim, Germany).
After the final PET scan, all animals were sacrificed 
by cervical dislocation under deep anesthesia and 
dissected. Organs were removed and levels of radioactivity 
were quantified using an aliquot of the injected radiotracer 
in a γ-counter (Wallac 1480 WIZARD 3” Gamma 
Counter; Perkin Elmer, Waltham, MA, USA) using an 
energy window between 350 and 650 keV. The results are 
expressed as % of the injected dose per g (%ID/g) of tissue 
or spleen-to-muscle ratios.
Histology
All organs were fixed in 4 % formalin and 
embedded in paraffin. For histological analyses, 3-5 µm-
thick sections were prepared and stained with hematoxylin 
and eosin (H&E). Immunohistochemistry was performed 
on an automated immunostainer (Ventana Medical 
Systems, Inc.), according to the manufacturer’s protocols 
for open procedures with slight modifications. All slides 
were stained with antibodies against Glut-1 (Abcam Inc., 
Suite B2304 Cambridge, USA). To detect the primary Y. 
enterocolitica YadA antibody a biotinylated anti-rabbit 
IgG secondary antibody (Vector Laboratories, Inc., 
Burlingame, USA) was used. Appropriate positive and 
negative controls were included to confirm the accuracy 
of the staining.
Immunofluorescence microscopy
For immunofluorescence staining, 2 x 107 
bacteria were centrifuged on polyethyleneimine-coated 
coverslips, fixed for 60 min with 4 % PFA in PBS (w/v) 
and subsequently blocked overnight with 1 % bovine 
serum albumin (BSA) in PBS (w/v) at room temperature. 
Staining was performed using polyclonal rabbit antibodies 
directed against YadA or [64Cu]NODAGA-YadA (1 mg/
ml each, diluted 1:5 in PBS), which were incubated with 
samples for 2 h in a dark chamber with a humidified 
atmosphere at room temperature. A 1:100 dilution of a 
Cy2-conjugated secondary goat-anti-rabbit IgG antibody 
(Dianova, Hamburg, Germany) was applied for 2 h at 
room temperature. Finally, cover slips were mounted 
with Mowiol. Fluorescent images were obtained using an 
upright DMRE fluorescence microscope (Leica, Wetzlar, 
Germany) equipped with a Leica b/w digital camera using 
Oncotarget10www.impactjournals.com/oncotarget
the 100x objective, optovar 1.6x and the Leica application 
suite software. All samples from the experiment were 
recorded using identical software settings (exposure, 
gamma correction). Images were processed and assembled 
into figures using Adobe Photoshop/Illustrator.
statistical analysis
Statistical significance was determined using a two-
tailed t-test. For experiments investigating more than 
two groups, statistical significance was calculated using 
a one-way analysis of variance (ANOVA) followed by 
Tukey’s multiple comparison test conducted with Origin 
8 software (OriginLab Corporation, Northampton, MA, 
USA). Data were considered statistically significant at 
p < 0.05. All quantitative data are shown as the mean ± 
1 standard deviation (SD). For t-tests, group sizes were 
determined based on reaching statistical significance at a 5 
% threshold and a power of 90 %, with the average values 
differing by 2 SD. In all multi-group comparisons, the 
statistical significance threshold of 5 % was adjusted based 
on Tukey-Kramer corrections according to group numbers.
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